<DOC>
	<DOCNO>NCT01021956</DOCNO>
	<brief_summary>The objective study evaluate safety ( first objective ) efficacy ( second objective ) experimental drug product , Stakel® , treatment neovascular AMD . The drug product activate patient exposure light specific wavelength ( `` Vascular Targeted Photodynamic therapy '' , `` VTP '' ) . The exploratory objective ass whether possible delay reduce requirement anti VEGF intravitreal therapy first 12 week VTP . All subject 52 week safety follow telephone call .</brief_summary>
	<brief_title>Safety Preliminary Efficacy Study WST11 ( Stakel® ) -Mediated VTP Therapy Subjects With CNV Associated With AMD</brief_title>
	<detailed_description>The primary objective Phase IIa clinical study evaluate safety treatment Stakel®-mediated VTP subject neovascular AMD . The secondary objective Phase IIa clinical study explore effect treatment Stakel®-mediated VTP subject neovascular AMD . The exploratory objective ass whether possible delay reduce requirement anti VEGF intravitreal therapy first 12 week VTP . All subject 52 week safety follow telephone call .</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<criteria>Twenty eight day least one ranibizumab injection , recurrent leakage FA subfoveal CNV secondary AMD . Total lesion size exceed 5400 μm great linear dimension . Best Corrected Visual Acuity ( BCVA ) letter score 73 23 study eye start distance 4 meter . No contraindication intravitreal ranibizumab injection . Postmenopausal least 12 month prior enrollment practice medically acceptable form birth control pregnant . Male subject must practice medically acceptable form birth control . Prior treatment : Previous subfoveal laser photocoagulation , externalbeam radiation therapy , transpupillary thermotherapy ( TTT ) study eye time . Using antiVEGF therapy indication ( e.g. , cancer ) 30 day prior study and/or study Received antiVEGF injection study eye le 28 day prior Day 1 study . More three previous photodynamic therapy ( PDT ) treatments precede 12 month . Laser photocoagulation ( juxtafoveal extrafoveal ) study eye within precede month . History vitrectomy , glaucoma filtering surgery , submacular surgery surgical intervention study eye . History corneal transplant study eye . Previous participation study investigational drug within 1 month precede Day 1 ( exclude vitamin mineral ) . Lesion Characteristics Permanent structural damage center fovea study eye , concurrent ocular systemic condition could contraindicate administration investigational drug , render subject high risk treatment complication . Subretinal hemorrhage study eye involve center fovea , size hemorrhage either ≥50 % total lesion area ≥1 disc area size . Subfoveal fibrosis atrophy study eye least 50 % lesion . CNV either eye due cause . Retinal pigment epithelial tear involve macula study eye . Concurrent Ocular Conditions Active intraocular inflammation ( grade trace ) current vitreous hemorrhage rhegmatogenous retinal detachment macular hole ( Stage 3 4 ) study eye . History idiopathic autoimmuneassociated uveitis either eye . Infectious conjunctivitis , keratitis , scleritis , endophthalmitis either eye . Aphakia absence posterior capsule study eye . Spherical equivalent refractive error study eye demonstrate morethan eight diopter myopia . Intraocular surgery ( include cataract surgery ) study eye within three month precede Day 1 . Uncontrolled glaucoma study eye .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Macular Degeneration</keyword>
	<keyword>Age Related Macular Degeneration</keyword>
	<keyword>Choroidal Neovascularization</keyword>
	<keyword>AMD</keyword>
	<keyword>CNV</keyword>
	<keyword>WST11</keyword>
	<keyword>Stakel</keyword>
	<keyword>Photodynamic therapy</keyword>
	<keyword>Vascular Targeted Photodynamic therapy</keyword>
	<keyword>VTP</keyword>
</DOC>